Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYB001 Booster Vaccination in Adults
NCT05602558Phase 3Unknown
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Recombinant Protein Vaccines
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing LYB001 with Placebo (2 arms). Primary endpoint: First occurrence of confirmed symptomatic COVID-19 incidence rate per person-years of follow-up. Status: unknown.
02
Drugs
recombinant sars-cov-2 vaccine (cho cell) lyb001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05602558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602558.